Recursion Pharmaceuticals, Inc.

RXRX

Generative AIPrecision medicineBiotech & pharmaceuticals

$3.25vs prev close▼-0.25(-7.14%)

$2.7752W Range$7.18

11% from low

+0.33 (+11.15%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.88%

1M +0.03%p

Holding ETFs

2 ETFs

ARKG · ARKK

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +0.6% · Market value +16.9% · Weight +0.03%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.07.14	BUY	ARKG	14,897	$3.34	$49.8K
26.07.13	BUY	ARKG · ARKK	132,372	$3.30	$436.8K
26.07.10	BUY	ARKG · ARKK	249,223	$3.56	$887.2K
26.07.09	BUY	ARKG · ARKK	23,335	$3.76	$87.7K
26.07.08	BUY	ARKG · ARKK	24,874	$3.72	$92.5K
26.07.07	BUY	ARKG · ARKK	16,650	$3.84	$63.9K
26.07.06	BUY	ARKG · ARKK	9,964	$3.96	$39.5K
26.07.02	BUY	ARKG · ARKK	16,099	$3.80	$61.2K
26.07.01	BUY	ARKG · ARKK	97,833	$3.67	$359.0K
26.06.30	BUY	ARKG · ARKK	605,171	$3.67	$2.2M
26.06.29	BUY	ARKG · ARKK	216,170	$3.69	$797.7K
26.06.26	BUY	ARKG · ARKK	609,643	$3.52	$2.1M
26.06.25	BUY	ARKG · ARKK	891,473	$3.34	$3.0M
26.06.24	BUY	ARKG	260,020	$3.23	$839.9K
26.06.11	SELL	ARKK	1,665,715	$3.15	$5.2M

07.14BUY

14,897

ARKGClose$3.34Est. total$49.8K

07.13BUY

132,372

ARKG · ARKKClose$3.30Est. total$436.8K

07.10BUY

249,223

ARKG · ARKKClose$3.56Est. total$887.2K

07.09BUY

23,335

ARKG · ARKKClose$3.76Est. total$87.7K

07.08BUY

24,874

ARKG · ARKKClose$3.72Est. total$92.5K

07.07BUY

16,650

ARKG · ARKKClose$3.84Est. total$63.9K

07.06BUY

9,964

ARKG · ARKKClose$3.96Est. total$39.5K

07.02BUY

16,099

ARKG · ARKKClose$3.80Est. total$61.2K

07.01BUY

97,833

ARKG · ARKKClose$3.67Est. total$359.0K

06.30BUY

605,171

ARKG · ARKKClose$3.67Est. total$2.2M

06.29BUY

216,170

ARKG · ARKKClose$3.69Est. total$797.7K

06.26BUY

609,643

ARKG · ARKKClose$3.52Est. total$2.1M

06.25BUY

891,473

ARKG · ARKKClose$3.34Est. total$3.0M

06.24BUY

260,020

ARKGClose$3.23Est. total$839.9K

06.11SELL

1,665,715

ARKKClose$3.15Est. total$5.2M

1 / 13

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

34,128,198

Portfolio Weight

0.88%

in ETF 2.4%

Est. Value

$119M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$7.22

vs Current ▲ +106.2% upside

Current$3.50

Low ~ High$4.00 ~ $10.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Morgan Stanley

Equal-Weight

$5.50

+57.14%

—

Maintain

2026-05-14

Needham

Buy

$8.00

+128.57%

—

Maintain

2026-05-07

JP Morgan

Overweight

$10.00

+185.71%

—

Maintain

2026-04-30

B of A Securities

Neutral

$6.00

+71.43%

—

Maintain

2026-02-26

Needham

Buy

$8.00

+128.57%

—

Maintain

2026-02-26

1 / 4

Avg Target

$7.22

vs Current ▲ +106.2% upside

Buy

7 analysts

Strong Buy 2Buy 1Hold 4

Low $4.00

Current $3.50

High $10.00

Firm	Position	Target	Upside	Close	Action	Date
Morgan Stanley	Equal-Weight	$5.50	+57.14%	—	Maintain	26.05.14
Needham	Buy	$8.00	+128.57%	—	Maintain	26.05.07
JP Morgan	Overweight	$10.00	+185.71%	—	Maintain	26.04.30
B of A Securities	Neutral	$6.00	+71.43%	—	Maintain	26.02.26
Needham	Buy	$8.00	+128.57%	—	Maintain	26.02.26

1 / 4

Price Information

Previous Close$3.50

Open$3.38

Day Range$3.37 - $3.63

52-Week Range$2.77 - $7.18

1-Year Change-27.54%

Trading Volume

Volume22,898,467

Avg Volume (3mo)21,067,322

Valuation

Market Cap1.9B

Book Value$1.71

Shares Outstanding535,342,170

Financials

Revenue (TTM)54.9M

Net Income-518,884,000

EPS$-1.00

EBITDA-471,604,000

Profitability

P/E Ratio-

P/B Ratio2.05

Return on Equity (ROE)-56.58%

Return on Assets (ROA)-27.33%

Profit Margin0.00%

EV/EBITDA-2.96

Beta1.05

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)60.81

Company Overview

Recursion Pharmaceuticals is a clinical-stage biotechnology company that industrializes drug discovery by integrating technology across biology, chemistry, and data science. They are developing multiple drug candidates for various diseases, including cerebral cavernous malformation, neurofibromatosis type 2, and certain cancers. Recursion partners with major pharmaceutical companies to advance its pipeline.

P/B

2.05

Price-to-Book

ROE

-56.6%

Persistent loss

Beta

1.05

Market Volatility

RSI(14)

60.8

Neutral zone

AI-generated summary. Not investment advice.

Recursion Pharmaceuticals, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks